List of Excipients in Branded Drug CHILDREN ASTEPRO ALLERGY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare LLC	CHILDREN ASTEPRO ALLERGY	azelastine hcl	0280-0066	BENZALKONIUM CHLORIDE
Bayer HealthCare LLC	CHILDREN ASTEPRO ALLERGY	azelastine hcl	0280-0066	EDETATE DISODIUM
Bayer HealthCare LLC	CHILDREN ASTEPRO ALLERGY	azelastine hcl	0280-0066	HYPROMELLOSES
Bayer HealthCare LLC	CHILDREN ASTEPRO ALLERGY	azelastine hcl	0280-0066	SODIUM CITRATE
Bayer HealthCare LLC	CHILDREN ASTEPRO ALLERGY	azelastine hcl	0280-0066	SORBITOL

Children’s Astepro Allergy Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Children’s Astepro Allergy is an over-the-counter azelastine hydrochloride nasal spray for temporary relief of nasal congestion, runny nose, sneezing, and itchy nose caused by seasonal or perennial allergic rhinitis in children ages 6 and older. Its commercial position depends less on active-ingredient exclusivity and more on pediatric usability, preservative tolerance, dose consistency, packaging, retailer access, and brand trust.

What is Children’s Astepro Allergy?

Children’s Astepro Allergy contains azelastine hydrochloride 0.1% in a metered nasal-spray formulation. Each spray delivers approximately 137 micrograms of azelastine hydrochloride. The product is administered as one spray per nostril twice daily for children ages 6 to 11, subject to the current product labeling.[1]

Attribute	Product profile
Brand	Children’s Astepro Allergy
Active ingredient	Azelastine hydrochloride
Strength	0.1% nasal spray
Dosage form	Metered-dose nasal spray
Route	Intranasal
FDA status	OTC drug
Indication	Allergic rhinitis symptoms
Pediatric population	Children age 6 years and older
Primary commercial owner	Bayer Consumer Health
Key formulation issue	Local tolerability and spray usability

Azelastine is an antihistamine. Unlike oral antihistamines, intranasal delivery places the drug at the nasal mucosa and can provide a direct local treatment option. The principal product liabilities are bitter taste, nasal irritation, epistaxis, and improper administration technique.

What excipients are used in Children’s Astepro Allergy?

The formulation uses conventional aqueous nasal-spray excipients. The FDA labeling and DailyMed information identify excipient categories that support pH control, tonicity, preservation, viscosity, chelation, and product stability.[1,2]

Excipient or excipient class	Likely formulation role	Commercial relevance
Purified water	Vehicle	Enables aqueous nasal delivery
Sodium chloride	Tonicity adjustment	Supports nasal comfort and isotonicity
Citric acid and phosphate buffer components	pH control	Supports chemical stability and tolerability
Hypromellose	Viscosity and spray-performance control	Can improve residence time and plume behavior
Disodium edetate	Chelating agent	Reduces metal-catalyzed degradation
Benzalkonium chloride	Preservative	Supports multidose container microbiological control

The exact quantitative composition is proprietary or label-dependent. Product developers should treat the listed excipient system as a platform architecture rather than assume that a direct generic copy can reproduce its performance with the same nominal ingredients.

How does the excipient system support commercial performance?

The commercial value of the formulation is concentrated in four technical functions.

1. Preservative protection

A multidose aqueous nasal spray is exposed to repeated handling and potential microbial contamination. Benzalkonium chloride is a conventional preservative for multidose nasal products. Its use reduces the need for single-use packaging, which lowers packaging material, freight, and consumer cost.

The tradeoff is tolerability. Repeated exposure to benzalkonium chloride has been associated with concerns about nasal mucosal irritation in some chronic-use settings. This creates an opportunity for preservative-free or lower-preservative competitors, particularly for consumers with frequent dosing or sensitive nasal tissue.

2. Spray consistency

The metered pump must deliver a reproducible volume across the product’s shelf life and dose count. Hypromellose can influence viscosity, suspension or solution behavior, plume geometry, drip, and mucosal residence time. These variables affect perceived quality even when the delivered azelastine dose meets specification.

A commercial competitor could differentiate through:

• Lower residual volume in the pump;
• Better dose uniformity near container exhaustion;
• Reduced dripping into the throat;
• Lower spray force;
• More consistent plume dispersion;
• Improved priming and re-priming behavior.

For pediatric users, these attributes are commercially significant because caregiver acceptance can determine repeat purchase.

3. Nasal comfort

Sodium chloride and buffer selection affect osmolarity and pH. A nasal formulation that is markedly hypertonic, hypotonic, or acidic may cause stinging and reduce adherence. The formulation target is a balance among drug stability, preservative efficacy, nasal comfort, and manufacturing robustness.

A developer could pursue a low-irritation platform using:

• A more physiologic tonicity profile;
• Alternative buffering systems;
• Reduced preservative exposure;
• Lower excipient concentration;
• Mucoadhesive polymers with improved sensory characteristics.

Any change must be evaluated for preservative effectiveness, spray performance, extractables and leachables, microbial quality, and local tolerability.

4. Taste and throat drip

Azelastine can produce a bitter taste when the spray drains posteriorly. Excipients alone may not eliminate this problem. Device geometry, droplet size, plume force, nozzle angle, and caregiver instruction can have greater commercial impact than flavoring.

A differentiated product could use a device-and-formulation combination that reduces posterior drainage. A flavor-masking approach would require careful assessment because many flavoring agents can irritate nasal tissue, affect stability, or create pediatric safety issues.

What regulatory status does Children’s Astepro Allergy have?

Astepro was originally marketed as a prescription azelastine nasal spray. The FDA approved the nonprescription switch for Astepro Allergy in 2021, allowing OTC use for adults and children ages 6 years and older.[3] Children’s Astepro Allergy is positioned within the OTC allergic-rhinitis market rather than as a new molecular entity.

Regulatory issue	Commercial implication
OTC status	Broad retail and e-commerce distribution
Pediatric age threshold	Market limited to children 6 years and older under current labeling
NDA-based product history	Supports manufacturing and safety credibility
Nasal-spray dosage form	Device performance is part of product quality
OTC labeling	Consumer comprehension and caregiver instructions are critical

The product is not a pediatric new chemical entity. Its market protection therefore comes primarily from brand, distribution, formulation know-how, device execution, regulatory compliance, and consumer marketing.

What patents protect Children’s Astepro Allergy?

The principal active ingredient, azelastine, is an established compound. Composition-of-matter exclusivity for azelastine is not a current commercial barrier. The practical IP opportunity is in secondary protection.

Potentially relevant patent categories include:

Patent category	Potential claim scope	Strength for a competitor
Formulation patents	Excipient ratios, pH, tonicity, preservative system	Moderate if narrowly claimed and technically differentiated
Device patents	Pump, actuator, nozzle, dose counter, plume geometry	Moderate to strong if the device is proprietary
Method-of-use patents	Specific age groups, dosing schedules, symptom treatment	Usually limited in an OTC market
Manufacturing patents	Mixing, filling, pump assembly, sterility or bioburden controls	Moderate operational value
Packaging patents	Child-resistant systems, dose tracking, leakage control	Commercially useful but often narrow
Trade secrets	Process controls, pump calibration, stability methods	Important even without broad patent coverage

A competitor should conduct a current patent and regulatory-record review before relying on any freedom-to-operate conclusion. The relevant search should include Bayer, Meda, azelastine hydrochloride, nasal spray pumps, preservative systems, and device suppliers across the United States, Europe, Canada, and major Asian markets.

Are Paragraph IV challenges relevant?

A Paragraph IV certification is generally associated with an abbreviated new drug application referencing an approved prescription drug. Children’s Astepro Allergy is an OTC product, so a direct Paragraph IV strategy against the consumer-labeled product is not the central competitive pathway.

A generic or private-label manufacturer may instead pursue:

• An ANDA referencing an eligible azelastine nasal-spray product;
• An OTC monograph route if the product satisfies applicable requirements;
• A marketed OTC product supported by its own regulatory pathway;
• A contract-manufacturing and private-label arrangement.

The regulatory route depends on the reference product, current FDA requirements, labeling, dosage form, and manufacturing status.

What formulation opportunities exist for competitors?

The strongest commercial opportunities are incremental improvements rather than a new active ingredient.

Preservative-free azelastine

A preservative-free product could target children who experience irritation or caregivers seeking a lower-exposure formulation. The principal barrier is multidose-container microbiological control. Viable approaches include:

• Unit-dose containers;
• One-way valve systems;
• Sterile pump systems;
• Preservative-free multidose devices;
• Smaller package sizes with controlled in-use dating.

The added packaging cost could be offset by premium positioning.

Low-drip pediatric spray

A formulation and device package designed to minimize throat drainage could improve taste acceptance. Relevant development variables include viscosity, droplet-size distribution, plume angle, actuation force, and nozzle geometry.

Fragrance-free and sensory-neutral formulation

Parents may prefer a product without unnecessary flavor or fragrance components. Sensory neutrality can support pharmacy, pediatric, and allergy-specialist channels, provided it does not worsen bitterness or irritation.

Extended-use and adherence packaging

A dose counter, lockout mechanism, color-coded actuator, or caregiver-oriented label could increase correct administration. Packaging improvements may produce stronger retail differentiation than small changes to buffer composition.

Combination products

Azelastine-fluticasone combinations already occupy an adjacent market segment. A children’s combination nasal spray could offer broader symptom control, but it would face more complex regulatory, safety, labeling, and formulation requirements. The combination pathway is not a simple excipient extension of Children’s Astepro Allergy.

How does Children’s Astepro Allergy compare with competing allergy products?

Product class	Example active ingredient	Main advantage	Main limitation
Intranasal antihistamine	Azelastine	Direct local antihistamine action and rapid symptom relief	Bitter taste and nasal irritation
Intranasal corticosteroid	Fluticasone, triamcinolone	Strong control of nasal inflammation	Technique, delayed perceived onset for some users
Oral antihistamine	Cetirizine, loratadine	Convenient systemic dosing	Possible drowsiness or systemic exposure
Saline spray	Sodium chloride	Low-risk supportive care	Does not provide antihistamine activity
Combination nasal spray	Azelastine plus fluticasone	Broad pharmacologic coverage	Higher complexity and cost

Children’s Astepro Allergy competes most directly with pediatric intranasal corticosteroids and oral antihistamines. Its excipient and device strategy should therefore address the reasons caregivers abandon nasal products: resistance to administration, throat taste, fear of irritation, leakage, and uncertainty about correct technique.

What commercial opportunities exist for manufacturers and licensees?

Private-label and retailer brands

Azelastine nasal spray has potential for retailer-branded allergy lines if the manufacturer can provide:

• Reliable pump supply;
• Stable long-term product;
• Consumer-ready packaging;
• Competitive cost of goods;
• Regulatory support;
• Consistent seasonal inventory.

Private-label products could compete on price, preservative-free positioning, or pediatric packaging.

Contract manufacturing

The product requires expertise in aqueous nasal manufacturing, pump assembly, microbiological control, and dose-uniformity testing. Contract manufacturers with existing nasal-spray capacity can create value through scale, dual sourcing, and shorter commercialization timelines.

Geographic expansion

Azelastine is marketed in multiple jurisdictions, but pediatric labeling, OTC classification, preservative restrictions, device rules, and language requirements vary. Attractive markets include countries with high allergic-rhinitis prevalence and established pharmacy-based self-care channels. The main geographic barriers are local registration, pediatric safety requirements, pharmacovigilance, and country-specific device qualification.

Premium formulation licensing

A licenseable platform could combine azelastine with:

• Preservative-free multidose delivery;
• A low-drip actuator;
• A dose counter;
• Improved nasal comfort;
• Child-resistant packaging;
• Stability-enhancing container systems.

The strongest licensing proposition would include comparative human-use data showing better tolerability or administration success, rather than relying only on a new excipient list.

How strong is the patent estate for Children’s Astepro Allergy?

The estate is likely stronger as a product-development and trade-secret position than as a broad active-ingredient monopoly. The active molecule is old, and standard excipients are generally difficult to protect broadly. Patent value would depend on narrow combinations that demonstrate an unexpected technical effect, such as improved stability, preservative efficacy at reduced concentration, superior dose uniformity, or reduced posterior deposition.

A practical strength assessment is:

IP asset	Estimated strategic value
Azelastine composition of matter	Low for current market exclusivity
Basic aqueous nasal formulation	Low to moderate
Specific excipient ratio and stability profile	Moderate
Proprietary pump or actuator	Moderate to high
Preservative-free multidose system	High if validated and patented
Manufacturing process	Moderate, often protected as trade secret
Brand and OTC consumer recognition	High commercial value, non-patent asset

What generic launch risks exist?

Generic and store-brand entry would likely pressure price before eliminating the branded product. The largest risks are:

1. Retail substitution and shelf-space loss.
2. Promotional discounts by pharmacy chains.
3. Competing azelastine products with similar labeling.
4. Reformulated products marketed as preservative-free.
5. Oral antihistamine and corticosteroid switching.
6. Seasonal demand volatility and inventory write-offs.
7. Pump-component shortages or manufacturing deviations.

Bayer can reduce exposure through pediatric packaging, device differentiation, retail exclusivity, digital adherence tools, and a product line that includes both children’s and adult formats.

Key Takeaways

• Children’s Astepro Allergy is an OTC azelastine hydrochloride 0.1% nasal spray for children age 6 and older.
• Its formulation uses conventional nasal-spray excipients for preservation, buffering, tonicity, viscosity, and stability.
• The main excipient opportunity is improved tolerability, especially through preservative-free or reduced-preservative delivery.
• Device performance, plume geometry, drip reduction, and dosing consistency may create more commercial value than a minor excipient change.
• Broad active-ingredient exclusivity is not the primary barrier to competition.
• Secondary patents, device claims, manufacturing know-how, packaging, and brand recognition are the relevant protection layers.
• Private-label, contract-manufacturing, preservative-free, and pediatric-device opportunities are the clearest commercial paths.
• Paragraph IV litigation is less central because the marketed product is an OTC consumer product rather than a conventional new prescription launch.

FAQs

Is Children’s Astepro Allergy preservative-free?

No. The marketed multidose nasal-spray formulation uses benzalkonium chloride as a preservative, according to product labeling.[1,2]

Can a competitor patent a new azelastine excipient combination?

Yes, but broad claims to standard excipients are difficult to sustain. A stronger application would link a defined composition to demonstrated stability, tolerability, preservative efficacy, or spray-performance benefits.

Is Children’s Astepro Allergy suitable for children under age 6?

The current OTC labeling is for children age 6 years and older. Use below that age requires a separate regulatory and clinical assessment.

Does a preservative-free azelastine spray have commercial potential?

Yes. It could command a premium among frequent users and consumers concerned about nasal irritation, although packaging and microbiological-control costs would increase.

What is the most valuable licensing asset in this market?

A validated preservative-free multidose nasal-delivery system with improved dose uniformity and reduced throat drip would likely have greater licensing value than a routine buffer or tonicity adjustment.

References

1. Bayer Healthcare LLC. (2024). Children’s Astepro Allergy: Drug facts and product labeling. U.S. Food and Drug Administration/DailyMed.

2. National Library of Medicine. (2024). Astepro azelastine hydrochloride nasal spray, metered. DailyMed.

3. U.S. Food and Drug Administration. (2021). FDA approves first over-the-counter nasal spray to treat allergies. https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-nasal-spray-treat-allergies

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs